Publikationen, an denen er mitarbeitet CARLOS SOLANO VERCET (119)

2024

  1. Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease

    Bone Marrow Transplantation, Vol. 59, Núm. 8, pp. 1118-1126

  2. Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir prophylaxis

    Bone Marrow Transplantation

  3. Comparative performance of the Platelia Aspergillus Antigen and Aspergillus Galactomannan antigen Virclia Monotest immunoassays in serum and lower respiratory tract specimens: a "real-life" experience

    Microbiology Spectrum, Vol. 12, Núm. 8

  4. Letermovir use may impact on the Cytomegalovirus DNA fragmentation profile in plasma from allogeneic hematopoietic stem cell transplant recipients

    Journal of Medical Virology, Vol. 96, Núm. 3

  5. Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy

    Infection

  6. Performance of the Roche Elecsys® IGRA SARS-CoV-2 test for the detection and quantification of virus-reactive T cells in COVID-19-vaccinated immunosuppressed patients and healthy subjects

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 7, pp. 1427-1436

  7. Torque Teno Virus DNA Load in Blood as an Immune Status Biomarker in Adult Hematological Patients: The State of the Art and Future Prospects

    Viruses, Vol. 16, Núm. 3

  8. Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy

    Bone Marrow Transplantation, Vol. 59, Núm. 1, pp. 93-100

  9. Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

    Mediterranean Journal of Hematology and Infectious Diseases, Vol. 16, Núm. 1

2023

  1. Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study

    Journal of medical virology, Vol. 95, Núm. 7, pp. e28933

  2. Cytomegalovirus DNAemia in haematological patients undergoing CD19-directed chimeric antigen receptor T-cell therapy: should it be systematically monitored?

    Clinical Microbiology and Infection

  3. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir

    Transplant Infectious Disease, Vol. 25, Núm. 2

  4. Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors

    British Journal of Haematology, Vol. 200, Núm. 6, pp. e58-e61

  5. Immunovirology of cytomegalovirus infection in allogeneic stem cell transplant recipients undergoing prophylaxis with letermovir: A narrative review

    Journal of Medical Virology, Vol. 95, Núm. 8

  6. Impact of cytomegalovirus immunodominant HLA-I donor–recipient matching on the incidence and features of virus DNAemia and virus-specific T-cell immune reconstitution in unmanipulated haploidentical hematopoietic stem cell transplantation

    Transplant Infectious Disease, Vol. 25, Núm. 3

  7. In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 36, Núm. 5, pp. 526-530

  8. Monitoring of plasma Torque teno virus, total Anelloviridae and Human Pegivirus 1 viral load for the prediction of infectious events and acute graft versus host disease in the allogeneic hematopoietic stem cell transplantation setting

    Journal of Medical Virology, Vol. 95, Núm. 9

  9. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

    Blood Cancer Journal, Vol. 13, Núm. 1

  10. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

    Viruses, Vol. 15, Núm. 10

  11. Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances

    Transplant Infectious Disease, Vol. 25, Núm. S1